ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

ORAL FLUDROCORTISONE TRIAL FOR SALT-PENETRATING SCREENING IN HYPERTENSIVE CASES

AUTHORS:

Dr Inayatullah, Dr. Ushna Khan Durrani, Dr. Maria Elahi

ABSTRACT:

Background: Salt affectability is related by enlarged cardiovascular danger, but best quality technique (diet cycles) requires 24-hour urine testing and has low consistency in patients. Purpose: To examine theory that oral fludrocortisone (0. mg daily for 1 week) is the decent option for distinguishing salt-sensitive cases. Methods: Researchers led the randomized hybrid review through 35 hypertensive persons involving accompanying advances: (1) time loss; (2) stage A (little also high sodium diet cycles); (3) elimination2; (4) stage B (fludrocortisone test). Our current research was conducted at Sir Ganga Ram Hospital, Lahore from April 2018 to March 2019. Stages A and B remained achieved arbitrarily. Based on the handwriting, we found that 54.5% of the subjects had a saline touch, as indicated by the baseline test. By means of ROC elbow, fludrocortisone trial characterized salt-affectability by the mean pulse increment of ≥4 mmHg. Decent fludrocortisone accuracy was observed in distinguishing salt affectability (AUC: 0.734±0.06; p<0.002), with 81% affectability and 54% explicitly. Conclusion: The fludrocortisone test is very decent choice for screening salt affectability in hypertensive cases. Though, little level of explicitness avoids the current trial from being a perfect substitute for concentrated work diet cycle test for salt affectability. Key words: Oral Fludrocortisone, Salt-Penetrating Screening, Hypertensive Cases.

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.